KIAA1755 is a protein that, similar to the LOC nomenclature, has been identified through systematic sequencing of large genomic regions but has not been thoroughly characterized in terms of function. The "KIAA" prefix denotes that the protein was first identified in a large-scale cDNA sequencing project conducted by the Kazusa DNA Research Institute in Japan. The number "1755" serves as a unique identifier for this specific protein within the KIAA project database.The KIAA1755 protein is encoded by a gene that is predicted based on the sequence of cDNA clones. The gene's mRNA expression patterns, as well as the predicted amino acid sequence of the protein, may provide preliminary clues about its function. Often, KIAA proteins are of interest because they may represent novel proteins with potential roles in cellular biology that have not been previously described.
The study of KIAA1755 would include examining its sequence for recognizable motifs, domains, or signatures that could suggest a biological function. For example, a DNA binding domain might imply a role in transcriptional regulation, while a kinase domain might suggest involvement in signal transduction pathways.Bioinformatics tools can be used to predict subcellular localization, post-translational modifications, and potential interaction partners for KIAA1755. Experimental approaches, such as gene knockdown or overexpression studies, protein interaction assays, and localization studies, are essential to confirm these predictions and determine the physiological role of KIAA1755.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
SERCA pump inhibitor, leads to increased cytosolic calcium levels, potentially affecting EFCAB14/KIAA1755 through calcium-related signaling pathways. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
Ionophore that increases intracellular calcium levels, potentially affecting EFCAB14/KIAA1755 activity by altering calcium-dependent signaling pathways. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $28.00 $53.00 | 37 | |
Modulates intracellular calcium release, potentially influencing EFCAB14/KIAA1755 activity through calcium signaling. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Increases intracellular calcium levels, potentially influencing EFCAB14/KIAA1755 activity through calcium-dependent signaling. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
Intracellular calcium chelator, could indirectly affect EFCAB14/KIAA1755 activity by modulating calcium signaling. | ||||||
EGTA | 67-42-5 | sc-3593 sc-3593A sc-3593B sc-3593C sc-3593D | 1 g 10 g 100 g 250 g 1 kg | $21.00 $65.00 $120.00 $251.00 $815.00 | 23 | |
Calcium chelator, used to study the role of extracellular calcium, could indirectly influence EFCAB14/KIAA1755. | ||||||
Nimodipine | 66085-59-4 | sc-201464 sc-201464A | 100 mg 1 g | $61.00 $307.00 | 2 | |
Calcium channel blocker, primarily L-type, potentially influencing EFCAB14/KIAA1755 activity by altering calcium influx. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Another calcium channel blocker, affects calcium influx, potentially influencing EFCAB14/KIAA1755 activity. | ||||||
Ryanodine | 15662-33-6 | sc-201523 sc-201523A | 1 mg 5 mg | $223.00 $799.00 | 19 | |
Modulates calcium release from sarcoplasmic/endoplasmic reticulum, could affect EFCAB14/KIAA1755 activity. | ||||||
SK&F 96365 | 130495-35-1 | sc-201475 sc-201475B sc-201475A sc-201475C | 5 mg 10 mg 25 mg 50 mg | $103.00 $158.00 $397.00 $656.00 | 2 | |
Inhibitor of store-operated calcium entry, potentially influencing EFCAB14/KIAA1755 activity. | ||||||